What is LiquiPuls™?

LiquiPuls™ is the patented  technical platform for new drug discovery and development. LiquiPuls™ is an innovative technology platform based on the principle of pulsed microdialysis and advanced technologies including nano-particle emulsion, optimized drug delivery, and controlled release. This platform provides unique characterization and analytical capabilities that other technologies cannot produce.

It is amongst one of the most advanced technologies to study supersaturated drug solutions and the drug release of complex drug systems (nanoparticles, microemulsions, liposomes, etc.) in the world. Liquipuls™ provides researchers with highly accurate, repeatable and reproducible data, which can be used to determine the concentration of free drugs dissolved in the medium immediately and precisely. Through these data, researchers can study multiphase systems on macro and micro scales. At the same time, LiquiPuls provides instantaneous resolution unmatched by any other technology, and its detection frequency can reach one datapoint every 10 seconds. 

What can LiquiPuls™ do?

LiquiPuls™ is a breakthrough technology, which fills many technical gaps in the field of pharmacy and can be applied in various system scenarios. First, a qualitative breakthrough has been made in the bioequivalence evaluation of complex preparations (ophthalmic emulsions and suspensions). The comparison between LiquiPuls™ method and traditional method (Franz Cells) in detecting drug release can fully reflect the advantages of LiquiPuls™. LiquiPuls™ quickly detects the release of most active ingredients (detection speeds are improved from levels of minutes down to seconds), but also demonstrates the ability to discriminate that  traditional methods do not have.

On February 3, 2022, co-authored with our co-inventors and co-developer of LiquiPuls, FDA officials published an article in the International Journal of Pharmaceutics, recognizing LiquiPuls™ as a promising method to determine the drug distribution within the oil-rich globule, surfactant-rich micelle and aqueous phases of the emulsion formulation.1

In addition to the above applications, LiquiPuls™ technology platform can also be applied to the following studies:

1) In vitro dissolution sampling of nanoparticles and supersaturated dosage forms to determine the concentration of free dissolved drugs (representing the absorbable forms of drugs) over time, including spring and parachute modes;

2) Nucleation and precipitation kinetics of supersaturated solutions;

3) Release of drugs from micelles and liposomes;

4) Drug distribution in microscopic multiphase systems, like microemulsions, micelles and liposomes;

5) In-situ solubility studies to evaluate the influence of excipients (such as polymers, sodium chloride, sucrose, etc.) on the solubility of poorly soluble drugs in aqueous solution;

6) In-situ drug distribution studies to determine the drug distribution in creams and gels;

7) Kinetics of drug binding and release with protein and other carriers;

8) Determination of drug transport characteristics and parameters;

9) Drug discovery and pharmaceutical formulation development;

10) Optimization of complex formulations.


 1 Bellantone R.A., Shah K.B., Patel P.G., Kaplan M., Xu X., Li V., Newman B. (2022).

Cyclosporine release and distribution in ophthalmic emulsions determined by pulsatile microdialysis. International Journal of Pharmaceutics, Volume 615 (1-2), 121251